Allakos — Corporate Update (August 2019)
41 slides from Allakos's corporate update, Aug 5, 2019
Slide 1: Phase 2 Eosinophil Gastritis and Gastroenteritis Study Results
Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Diseases Phase 2 Eosinophil Gastritis and Gastroenteritis Study Results Aug 5, 2019 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. (“Allakos,” the “Company,” “we” or “our”); the generation of future value; b
Slide 3: Agenda
Agenda Robert Alexander, PhD Overview 5:00 – 5:15 AM Henrik Rasmussen, MD PhD Results of the ENIGMA Phase 2 Study 5:15 – 5:45 AM Evan Dellon, MD MPH Physician Perspective 5:45 – 5:55 AM Q&A 5:55 AM
Slide 4: Overview
Overview Robert Alexander, PhD CEO – Allakos
Slide 5: Executive Summary
Executive Summary AK002 met all prespecified primary and secondary endpoints in EG/EGE Randomized, double-blind, placebo-controlled study results showed: 95% reduction in tissue eosinophils vs. placebo +10% (p < 0.0001) 69% treatment response rate vs. placebo 5% (p = 0.0008) 53% decrease in symptom
Slide 6: Mast Cells and Eosinophils: Effector Cells Central to Inflammatory Responses
Mast Cells and Eosinophils: Effector Cells Central to Initiating and Maintaining Inflammatory Responses Found at the Internal/External Interface of the Body In particular, in tissues and surrounding blood vessels and peripheral nerves Produce a Broad Range of Inflammatory Mediators Vasoactive amines
Slide 7: AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils
AK002 Developed to Target Siglec-8 on Mast Cells and Eosinophils Cell Membrane Activating Receptors Activation Siglec-8 Mast cell Eosinophil Inflammatory response AK002 Inhibition Mast cell Eosinophil Inhibition ADCC/Apoptosis AK002
Slide 8: Mast Cells and Eosinophils are Key Drivers of Inflammatory Disease
Mast Cells and Eosinophils are Key Drivers of Inflammatory Disease T Cell B Cell Activated B Cell Mast Cell IgE Activation and Recruitment of Other Immune Cells and Tissue Inflammation Macrophage Eosinophil Neutrophil Allergens Smooth Muscle Neuron Epithelium ACUTE AND CHRONIC INFLAMMATION SENSITIZA
Slide 9: Eosinophils and Mast Cells Play a Significant Role in Many Diseases
Eosinophils and Mast Cells Play a Significant Role in Many Diseases Mast Cell Activation Syndrome Indolent Systemic Mastocytosis Chronic Urticaria Atopic Dermatitis Eosinophilic Gastritis Eosinophilic Esophagitis Eosinophilic Gastroenteritis Ulcerative Colitis Vernal Keratoconjunctivitis GASTROINTES
Slide 10: Eosinophilic Gastrointestinal Diseases (EGIDs)
Eosinophilic Gastrointestinal Diseases (EGIDs) ESOPHAGUS STOMACH DUODENUM/ SMALL INTESTINE Eosinophilic Gastritis (EG) Eosinophilic Esophagitis (EoE) Eosinophilic Gastroenteritis (EGE) = US Prevalence ~20-25K ~25K ~200K EG, EGE, EoE Chronic Eosinophilic Inflammation of the Stomach, Small Intestine,
Slide 11: Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2 Study
Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Phase 2 Study Henrik S. Rasmussen, MD PhD Chief Medical Officer - Allakos
Slide 12: ENIGMA Phase 2 Study Design
ENIGMA Phase 2 Study Study Design Randomized, double-blind, placebo-controlled study in EG/EGE Active moderate to severe symptoms Biopsy confirmed EG/EGE Stomach: ≥30 eos/high powered field (hpf) in 5 hpfs Duodenum: ≥30 eos/hpf in 3 hpfs 65 Patients – 3 arms 22 patients 0.3, 1.0, 1.0, 1.0 mg/kg 21 p
Slide 13: Symptoms Assessed Using Proprietary PRO
Symptoms Assessed Using Proprietary PRO Abdominal pain Nausea Vomiting Early satiety Loss of appetite Abdominal cramping Bloating Diarrhea Developed in accordance with FDA guidance on PRO development Captures the symptoms of EG/EGE patients on a daily basis Measures 8 symptoms each on a scale of 0-1
Slide 14: Prespecified Hierarchical Analysis Per Protocol
Prespecified Hierarchical Analysis Per Protocol Primary Endpoint Mean percent change in gastrointestinal eosinophil counts from baseline Responder Secondary Endpoint Proportion of patients who have: >75% decrease in tissue eosinophils AND >30% benefit in Total Symptom Score (TSS) Symptoms Secondary
Slide 15: Baseline Characteristics
Baseline Characteristics AK002 (n=39) Placebo (n=20) Total (N=59) Age, Median (Range) 43 (18-74) 40 (18-67) 42 (18-74) Female 72% 50% 64% EoE with Dysphagia 38% (15) 50% (10) 42% (25) % of Patients with AEC1 <500 eos/µL 74% 60% 69% % of Patients with AEC1 <1500 eos/µL 95% 95% 95% Mean Baseline Gastr
Slide 16: Primary Endpoint Met for All AK002 Groups
Primary Endpoint Met for All AK002 Groups Treatment Arm Baseline Eosinophil Counts / hpf Mean %∆ in Eosinophil Counts p - value High Dose AK002 (n=20) 76 -97% <0.0001 Low Dose AK002 (n=19) 80 -92% <0.0001 Combined AK002 (n=39) 78 -95% <0.0001 Placebo (n=20) 75 +10% -
Slide 17: AK002 Demonstrates Potent Tissue Eosinophil Depletion
37 of 39 patients had < 5 eos/hpf Stomach/Duodenal Eos < 5/HPF AK002 Demonstrates Potent Tissue Eosinophil Depletion % of Patients AK002 Placebo (0/20) (37/39)
Slide 18: AK002 Met Patient Reported Symptoms Secondary Endpoint
AK002 Met Patient Reported Symptoms Secondary Endpoint Statistically significant improvements in symptoms observed 1 day after first infusion and maintained throughout the study Treatment Arm Baseline TSS Mean % Change in TSS p - value High Dose AK002 (n=20) 34 -58% 0.0012 Low Dose AK002 (n=19) 35 -
Slide 19: Higher Proportion of Patients with >50% Reduction in TSS on AK002 vs. Placebo
Higher Proportion of Patients with >50% Reduction in TSS on AK002 vs. Placebo Confidential % of Patients Placebo High Dose High/Low Low Dose AK002 EG/EGE-PRO Total Symptom Score: >50% Reduction (3/20) (13/20) (25/39) (12/19)
Slide 20: Improvement Across All Symptoms Measured on AK002
Improvement Across All Symptoms Measured on AK002 Confidential EG/EGE-PRO Symptom Score AK002 (n=39) Median Score -59% -79% -100% -65% -61% -57% -47% -55% Baseline End of Tx
Slide 21: AK002 Met Treatment Responder Secondary Endpoint
AK002 Met Treatment Responder Secondary Endpoint Treatment Arm Treatment Responders p - value High Dose AK002 (n=20) 70% 0.0009 Low Dose AK002 (n=19) 68% 0.0019 Combined AK002 (n=39) 69% 0.0008 Placebo (n=20) 5% - Treatment responder defined as: >75% reduction in tissue eosinophil counts AND >30% re
Slide 22: Additional Analyses
Additional Analyses
Slide 23: Endpoint Sensitivity Analyses
Endpoint Sensitivity Analyses Intent to Treat (ITT): All patients randomized (n=65) Includes Per Protocol (n=59) population plus: 2 patients only received 1 dose of drug 1 patient did not complete PRO 3 patients had their daily steroid dose altered Safety evaluated on the ITT population Protocol all
Slide 24: All Analyses Show Consistent Results
All Analyses Show Consistent Results Primary and Secondary Endpoint p-values AK002 Dose Groups Placebo High (n=20/16/21) Low (n=19/12/22) High/Low (n=39/28/43) (n=20/13/22) 1° - Tissue Eosinophils % Δ from BL to Day 99 Per Protocol <0.0001 <0.0001 <0.0001 - No Steroids <0.0001 <0.0001 <0.0001 - ITT
Slide 25: Eosinophilic Esophagitis Patients
Eosinophilic Esophagitis Patients AK002 (n=15) Placebo (n=10) Total (N=25) Age, Median (Range) 34 (18-68) 34 (21-53) 34 (18-68) Female 67% 40% 56% Mean Baseline Esophageal Eosinophils/hpf 43 79 56 Mean Baseline Esophageal Mast Cells/hpf 28 36 31 Mean Baseline Dysphagia Score 4.0 4.4 4.2
Slide 26: Significant Eosinophil Reductions in Patients With EoE
Esophageal Eos < 5/HPF1 Significant Eosinophil Reductions in Patients With EoE % of Patients AK002 Placebo *p <0.0001 * 13 of 14 patients had < 5 eos/hpf (1/9) (13/14) 1Excludes patients with eos < 5/hpf at baseline
Slide 27: Substantial Improvement in Dysphagia
Severity of Dysphagia1 Substantial Improvement in Dysphagia Histological and symptomatic improvement provides strong proof of concept in EoE 1All EoE patients with end of treatment dysphagia scores Mean %∆ from BL AK002 (n=12) Placebo (n=8)
Slide 28: Mast Cell Counts Decrease on AK002
Mast Cell Counts Decrease on AK002 Mast Cells in Gastric, Duodenal, and Esophageal Biopsies Baseline Day 99 Mean Peak Cell Count / hpf -17% -26%* -20% -3% +1% -9% *p <0.05 n= 39 39 BL=22, Day 99 = 21 20 20 BL=12, Day 99 = 10 AK002 Placebo
Slide 29: Safety Summary
Safety Summary
Slide 30: Safety: Treatment-Emergent AEs in ≥5% of Patients
Safety: Treatment-Emergent AEs in ≥5% of Patients % of Patients, (n) AK002 (n=43) Placebo (n=22) Infusion related reaction 60% (26) 23% (5) Headache 9% (4) 9% (2) Upper respiratory tract infection 9% (4) 9% (2) Urinary tract infection 9% (4) 5% (1) Nausea 7% (3) 14% (3) Fatigue 7% (3) 9% (2) Diarrhe
Slide 31: Safety Summary
Safety Summary Generally well tolerated Most common AE was mild to moderate infusion related reactions (IRR) 60% of AK002 patients vs 23% placebo 93% mild to moderate (flushing, feeling of warmth, headache, nausea, dizziness) Mostly on first infusion, greatly reduced or does not occur on subsequent
Slide 32: Open-Label Extension & Next Steps
Open-Label Extension & Next Steps
Slide 33: Extension Study Status
Extension Study Status 92% of patients elected to enter long-term extension study Current median duration of treatment 3 months Efficacy appears to improve with continued dosing Optimizing dose administration Pre-dose with oral prednisone 1 day prior to first and second AK002 doses No IRRs observed
Slide 34: EG/EGE and EoE Next Steps
EG/EGE and EoE Next Steps Q4 2019/Q1 2020 End of phase 2 meeting Q1 2020 Estimated phase 3 study start eosinophilic gastritis and/or eosinophilic gastroenteritis Q1 2020 Estimated phase 2/3 study start in eosinophilic esophagitis
Slide 35: Evan S. Dellon, MD MPH
Evan S. Dellon, MD MPH TITLE:Professor of Medicine, Gastroenterology & Epidemiology Director, Center for Esophageal Diseases and Swallowing Director, CGIBD Biostatistics and Clinical Research Core INSTITUTION:University of North Carolina School of Medicine SPECIALTY:Gastroenterology FOCUS:Epidemiolo
Slide 36: Corporate Updates
Corporate Updates
Slide 37: Strong Balance Sheet and Significant IP Protection
Strong Balance Sheet and Significant IP Protection Cash, Cash Equivalents and Investments in Marketable Securities as of June 30, 2019 $153.1M Q2 2019 Operating Expenses $20.1M AK002 US patents run until 2035 Lonza currently manufactures AK002
Slide 38: Anticipated Near-term Milestones
Anticipated Near-term Milestones Q1’20 Phase 3 EG/EGE and EoE Study starts H2’20 Phase 1 Data For subcutaneous AK002 Q4’19/Q1’20 End of Phase 2 Meeting Q1’20 Phase 1 Data in Mast Cell GI H1’20 Phase 2 Extension Data in EG and/or EGE
Slide 39: Experienced Management Team
Experienced Management Team Previous Experience Robert Alexander, PhD Chief Executive Officer CEO, ZS Pharma Director Alta Partners; Business Development, Genentech Adam Tomasi, PhD President & COO CSO & Head of Corporate Development, ZS Pharma Principal Alta Partners, Drug Discovery, Gilead, Cytoki
Slide 40: Executive Summary
Executive Summary AK002 met all prespecified primary and secondary endpoints in EG/EGE Randomized, double-blind, placebo-controlled study results showed: 95% reduction in tissue eosinophils vs. placebo +10% (p < 0.0001) 69% treatment response rate vs. placebo 5% (p = 0.0008) 53% decrease in symptom
Slide 41: All ako orn
All ako orn